Literature DB >> 20160454

'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.

Astrid Sydow1, Eva-Maria Mandelkow.   

Abstract

BACKGROUND: Aggregates of the tau protein are a hallmark of Alzheimer's and several other neurodegenerative diseases. Various transgenic mouse models have been generated to study the aggregation process. Since wild-type tau is highly soluble and does not aggregate readily, most models make use of tau mutations that occur in human frontotemporal dementias and are more prone to aggregate. These mouse models show neurofibrillary tangles similar to those of Alzheimer's disease. However, since the mice contain both endogenous wild-type mouse tau and exogenous human mutant tau, the relative contribution of these components to the aggregates has been a matter of debate.
OBJECTIVE: Using a new set of regulatable transgenic mouse models, we sought to determine whether mouse tau coaggregates with human tau when it is switched on. Furthermore, we asked what type of tau remains in the aggregates after switching off the expression of exogenous tau.
METHODS: We generated doxycycline-inducible transgenic mice expressing either full-length human tau or the tau repeat domain (tau(RD)). In addition, both types of human tau derivatives were expressed in a 'proaggregant' form (with the frontotemporal dementia with parkinsonism linked to chromosome 17 mutation DeltaK280), or in an 'antiaggregant' form (with additional proline mutations to block beta-structure and aggregation).
RESULTS: The proaggregant tau(RD) mice develop tangles rapidly after induction, the antiaggregant mice do not. Analysis by biochemistry and immunohistology reveals that the tangles contain both exogenous and endogenous mouse tau. After switching off the proaggregant tau(RD), tangles persist for extended periods. However, they are composed entirely of mouse tau.
CONCLUSIONS: Mouse tau and exogenous human tau can coaggregate in transgenic models of tauopathy. The aggregates are in dynamic equilibrium with their subunits, so that exogenous tau disappears when its expression is switched off. Once the seeds of aggregation are generated by the foreign tau species, they propagate in a 'prion-like' fashion within the cell even after the foreign tau has disappeared. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160454     DOI: 10.1159/000283479

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  19 in total

1.  Cell biology. A unifying role for prions in neurodegenerative diseases.

Authors:  Stanley B Prusiner
Journal:  Science       Date:  2012-06-22       Impact factor: 47.728

2.  In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice.

Authors:  Kaoru Yamada; John R Cirrito; Floy R Stewart; Hong Jiang; Mary Beth Finn; Brandon B Holmes; Lester I Binder; Eva-Maria Mandelkow; Marc I Diamond; Virginia M-Y Lee; David M Holtzman
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

3.  Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.

Authors:  B Michael Silber; Satish Rao; Kimberly L Fife; Alejandra Gallardo-Godoy; Adam R Renslo; Deepak K Dalvie; Kurt Giles; Yevgeniy Freyman; Manuel Elepano; Joel R Gever; Zhe Li; Matthew P Jacobson; Yong Huang; Leslie Z Benet; Stanley B Prusiner
Journal:  Pharm Res       Date:  2013-02-16       Impact factor: 4.200

4.  Reversibility of Tau-related cognitive defects in a regulatable FTD mouse model.

Authors:  Astrid Sydow; Ann Van der Jeugd; Fang Zheng; Tariq Ahmed; Detlef Balschun; Olga Petrova; Dagmar Drexler; Lepu Zhou; Gabriele Rune; Eckhard Mandelkow; Rudi D'Hooge; Christian Alzheimer; Eva-Maria Mandelkow
Journal:  J Mol Neurosci       Date:  2011-08-06       Impact factor: 3.444

5.  Polymeric alkylpyridinium salts permit intracellular delivery of human Tau in rat hippocampal neurons: requirement of Tau phosphorylation for functional deficits.

Authors:  Dave J Koss; Lianne Robinson; Anna Mietelska-Porowska; Anna Gasiorowska; Kristina Sepčić; Tom Turk; Marcel Jaspars; Grazyna Niewiadomska; Roderick H Scott; Bettina Platt; Gernot Riedel
Journal:  Cell Mol Life Sci       Date:  2015-06-13       Impact factor: 9.261

Review 6.  Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer's Disease: A Hypothesis.

Authors:  Shweta Kishor Sonawane; Subashchandrabose Chinnathambi
Journal:  J Mol Neurosci       Date:  2018-07-07       Impact factor: 3.444

7.  Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability.

Authors:  Susanne Wegmann; Yu Jin Jung; Subashchandrabose Chinnathambi; Eva-Maria Mandelkow; Eckhard Mandelkow; Daniel J Muller
Journal:  J Biol Chem       Date:  2010-06-21       Impact factor: 5.157

8.  The Dynamics and Turnover of Tau Aggregates in Cultured Cells: INSIGHTS INTO THERAPIES FOR TAUOPATHIES.

Authors:  Jing L Guo; Arjan Buist; Alberto Soares; Kathleen Callaerts; Sara Calafate; Frederik Stevenaert; Joshua P Daniels; Bryan E Zoll; Alex Crowe; Kurt R Brunden; Diederik Moechars; Virginia M Y Lee
Journal:  J Biol Chem       Date:  2016-04-18       Impact factor: 5.157

9.  Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.

Authors:  Illana Gozes
Journal:  EPMA J       Date:  2010-06-12       Impact factor: 6.543

10.  Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau.

Authors:  Ann Van der Jeugd; Katja Hochgräfe; Tariq Ahmed; Jochen M Decker; Astrid Sydow; Anne Hofmann; Dan Wu; Lars Messing; Detlef Balschun; Rudi D'Hooge; Eva-Maria Mandelkow
Journal:  Acta Neuropathol       Date:  2012-04-25       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.